In North America, DHL plans to invest over $1.1 billion, focusing on high-margin niche markets. The Americas will receive 50% of the total investment, with 25% allocated to Asia Pacific and 25% to the EMEA region. This expansion will enhance infrastructure and technology in storage, order fulfillment, distribution, global shipping, and last-mile delivery under the new DHL Health Logistics brand.

A significant portion of the funding will be directed toward establishing Good Distribution Practices-certified “Pharma Hubs,” developing multi-temperature shipment lanes, expanding cold chain capacity, and acquiring more temperature-controlled vehicles.

DHL operates nearly 600 sites dedicated to life sciences and health care logistics across 130 countries. The recent acquisition of Cryopdp, which specializes in logistics for clinical trials and biopharma, supports this focus. Additionally, DHL enhanced its e-commerce capabilities by acquiring Inmar Supply Chain Solutions, positioning itself as the largest provider of reverse logistics solutions in North America.

DHL faces competition from UPS and FedEx, both actively targeting growth in the life sciences segment. UPS recently acquired Germany’s Frigo-Trans, enhancing its temperature-controlled logistics capabilities across Europe. FedEx has prioritized health care as a key business vertical, aiming to generate nearly $400 million in new annualized health care revenue in the coming months.

Alongside its growth initiatives, DHL is implementing cost-cutting measures to achieve $1.1 billion in savings by 2030, including plans to cut 8,000 jobs at Deutsche Post.

As DHL invests in its health care logistics capabilities, it remains committed to delivering integrated, faster, and more reliable logistics solutions to meet the critical needs of the health care sector.